Flat revenue, 17% profit miss—strategic inventory build masks weak execution
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Delivered revenue within ₹1 Cr of guidance (₹858 vs ₹861); met prior-year margin guidance (stable-to-soft) but profit fell 17% YoY on volume de-growth.
Cautiously Optimistic
next 1–2 quarters
Cautiously Optimistic
multi-year
Q2 delivered a flat revenue but 17% PAT miss, with margin compression QoQ and elevated inventory. Management framed this as strategic (new product mix, inventory build for rabi). Upside hinges on rabi monsoon recovery and pricing power in H2; downside risk is high if commodity/demand remains soft. Near-term execution risk elevated; medium-term dependent on unforecast-able rainfall.
₹858 Cr
Revenue · −0.3% YoY₹85 Cr
Reported PAT · −16.7% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Q2 revenue ₹858 Cr, flat YoY growth with 5% offset by volume de-growth
METRevenue ₹858 Cr (vs ₹861 prior year) = -0.3% YoY; price growth 5% offset by volume decline = claim supported
EBITDA ₹126 Cr, down 18% YoY from ₹154 Cr
METEBITDA claim of 18% decline from ₹154 to ₹126 mathematically correct (₹154 × 0.82 ≈ ₹126)
PAT ₹85 Cr, down 17% from ₹102 Cr QoQ
METPAT ₹85 Cr vs prior year ₹102 Cr = 16.7% decline (mgmt stated 17%, minor rounding); Delivered result confirms ₹85 Cr
Crop Care +4% growth to ₹788 Cr via 6% price + 2% volume
METCrop Care segment ₹788 Cr claimed growth of 4%; prior year ₹760 Cr, math checks (₹760 × 1.04 ≈ ₹790, close)
Seeds revenue down 31% to ₹70 Cr due to 26% volume decline
METSeeds fell ₹101 Cr → ₹70 Cr = 30.7% decline; claimed 31% matches. Volume decline 26% given as driver.
Domestic B2C 1% de-growth via 5% price, 6% volume decline
MET₹556 Cr vs ₹562 Cr = -1.1% decline; math consistent with claimed price/volume mix
Managementframed margin compression as inventory strategy and channel discipline, not operational failure
OVERSTATEDDelivered: OPM 16.3%, NPM 9.8%, QoQ PAT -32%. Claim frames it as strategic; reality shows material profit miss YoY and QoQ despite flat revenue. Overstated.
Earnings quality
What changed since the last call
Seeds revenue plunged 31% YoY
DowngradeQ1 FY27 seeds were soft due to late monsoon and slow liquidation. Q2 worsened: North India cotton acreage down 20-25%; supply chain disruption from government water policy; illegal seed market inflated. Management now expecting selective 'crop holiday' due to inventory.
New product launches scaled to 9 FY27 (vs 0 prior year clarity)
UpgradeQ2 saw 4 new launches (Silentra, Marcellus, Biltox, Trynage) in crop care. Seeds added 6 new varieties. CSM export business saw 12x growth from ₹2 Cr (Q2FY26) to ₹27 Cr (Q2FY27), though from very low base.
Inventory strategy shifted to precautionary build
NewPrior 2 years, Rallis faced seed shortage (lost supply to farmers). This year, deliberately carrying 30-50% forward inventory 'at gross level' to secure rabi season. A response to prior-year miss; increases working capital but signals confidence in demand.
Export market re-strategized for margin over volume
NeutralB2B exports fell 2.5% but margins protected. Management stated deliberate deprioritization of low-margin export business to focus on domestic; added new customers/products in Americas/ASEAN.
The Q&A
Analysts pressed hard on inventory levels (Prashant Biyani), margins (Riju, Abhijit Akella), and seeds pricing recovery (Rohit Nagraj, Siddharth Gadekar). Management held its ground—defended inventory as strategic, explained margin compression as mix/timing, acknowledged seed headwinds but framed rabi as recovery opportunity. Tone steady but not fully convincing on near-term catalysts.
Sales returns & kharif liquidation — Rohit Nagraj, 360 ONE Capital
AnsweredMD stated kharif-related returns for majority of market completed by Sept. Some crops (cotton, delayed areas) may have staggered returns. Provisions taken for remainder.
Channel inventory management — Rohit Nagraj, 360 ONE Capital
AnsweredConscious market-based approach adopted this year (vs past uniform placement). Inventory only placed where demand water situation certain. Not flooding channel; level appropriate to market.
Seed availability & pricing for 2027 kharif — Rohit Nagraj, 360 ONE Capital
PartialDecent inventory carry-forward (soft seed season). Ability to increase prices dependent on monsoon forecast/sentiment. Hedged on specifics; noted last year good production, this year soft due to late season.
Inventory elevation vs H1 prior-year — Prashant Biyani, Elara Securities
AnsweredCombination of factors. War-driven precautionary build; seed inventory fresh (March harvest). Trying to pass cost increases to customers but demand soft, realistic to hold cost increase. Some inventory normalizing into next season.
Fungicide & herbicide pricing amid excess supply — Rajat Setiya, ithought PMS
PartialFungicide saw good demand uptick; herbicide low-pressure but fungicide segment up. Excess supply in market; consumption down so price pressure. Prices difficult. Company insecticide did well, herbicide had pressure, fungicide had margin uptick.
Export market growth amid geopolitical stress — Riju, Antique Stock Broking
AnsweredHighly dynamic environment. China now competes with India for export routes (closer to US). Supply chain 2-4 weeks delayed. Dedicated customers being served; some new additions in ASEAN, Africa. Margins protected even as volumes pressured.
Cotton market & illegal seed dynamics — Siddharth Gadekar, Equirus Capital
AnsweredCotton acreage down 20-25%. Illegal seed ~25-30% of market. Company held market share in North despite reduced volumes. Strategy: wait for illegal player performance and recovery; cotton acreage will rebound. Conservative framing given uncertainty.
Maize crop outlook post-government ethanol policy — Rajkumar Vaidyanathan, RK Investments
PartialMaize areas Bihar/Coastal Andhra (irrigation) will fare okay. Inland/rain-fed challenged due to water stress. Policy cap on ethanol is dampener but not sudden shift. Prices attractive; acreage may hold or grow. Speculative but foundational.
Capex run-rate & working capital trajectory — Abhijit Akella, Kotak Securities
AnsweredCapex prudent, H1 low but H2 will accelerate >INR50 Cr annually. NWC elevated (seed inventory, cost inflation, delayed receivables) but normalizing as season progresses. By March no red flag; combinations of elevated inventory + delayed season expected to ease.
Revenue composition & new product contribution — Abhijit Akella, Kotak Securities
AnsweredNew product launches (FY27) contributing ~₹100 Cr annualized. Product churn systematic: dropped ~₹100 Cr of old products over 3 years; added ~₹200 Cr new since. Net contribution positive; helps margin via portfolio mix and new segment participation.
Guidance
FY27 agrochemical industry growth 6-8% (unchanged from Q1 FY27 guidance)
MediumManagement reiterated industry growth tag (not company-specific FY27 target). Conditional on rabi recovery post-El Niño; no company-specific FY27 revenue number provided.
Margins guided stable-to-soft; no numeric FY27 OPM/NPM target
LowReaffirmed stable-to-soft stance but hedged on specifics. Contingent on input costs, commodity prices, and demand recovery. No quantified FY27 margin target.
Capex >INR50 Cr annually; R&D centre (Navi Mumbai) priority spend
MediumH1 capex was cautious due to uncertain environment. H2 to accelerate. Long-term capex philosophy: improve capital efficiency, prioritize growth initiatives & R&D.
Risks the call surfaced
Monsoon & rainfall dependency
HighEl Niño-induced deficient rains (2026 kharif ~19% below normal) crushed seed acreage & demand. Rabi 2026-27 critical; IMD 88-112% normal forecast has wide band. If shortfall repeats, seeds/crop care demand will contract further.
Seed business structural decline
HighSeeds revenue fell 31% YoY (₹101 Cr → ₹70 Cr). North India cotton crisis (pest pressure, pink bollworm, government water-release delays, illegal seed inflation) caused 26% volume decline. If acreage recovery slow, seeds margin contribution remains depressed.
Pricing power limited despite commodity strength
HighAchieved +5% price growth in crop care but offset by -6% volume decline. Farm economics weak; demand inelastic despite high commodity prices (fertilizer, energy). Management acknowledged inability to pass full cost increases in crop protection due to excess supply.
Inventory elevation & working capital stress
MediumSeed inventory deliberately elevated 30-50% of next year's requirement due to prior-year shortage experience. Raw material costs also inflated. Cash balance ₹211 Cr (30% of quarterly revenue) adequate but WC cycle elongating. Risk: if rabi demand disappoints, inventory forced liquidation at low prices.
Export market headwinds & geopolitical stress
MediumB2B exports fell 2.5% to ₹165 Cr despite 10% price growth. Red Sea logistics disruption, Europe instability, China competition, freight/container scarcity, shipping delays (2-4 weeks cumulative). Export margin defended through deliberate repricing; volume at risk.
Competitive consolidation & market share risk
MediumSmaller unorganized players facing working-capital stress (container costs, freight delays, poor demand). Some consolidation expected; larger players gaining share through scale. Rallis has moat (brand, R&D, distribution) but exposure to industry churn.
Management
Score 6/10. Clear on facts and numbers; transparent on headwinds (rain, pricing pressure). However, forward guidance vague (no FY27 numeric targets); heavy reliance on hypothetical rabi recovery. Hedged significantly on near-term visibility. Mixed. Hit revenue guidance (flat ₹858 Cr as expected) but profit miss significant (₹85 Cr vs ₹102 prior year = -17%). Margin compression defended as strategic but execution gap evident. New product contribution (₹100 Cr annualized) early-stage, not yet proven in profit.
1 · Dec 2026–Mar 2027
Rabi season outcome (rainfall, crop acreage, pricing). Management expects 'significantly better' if normal monsoon; material upside if realized.
2 · Q3 FY27 (Oct–Dec 2026)
New product contribution ramp (₹100 Cr annualized sales from 9 FY27 launches). Execution risk if adoption slower than forecast.
3 · Apr 2027
R&D centre (Navi Mumbai) commissioning. Strategic lever for innovation pipeline; long-term moat building.
Near-term execution risk elevated; medium-term dependent on unforecast-able rainfall.
Informational and educational content only. Not investment advice.